PRP for liver regeneration: Hope for fibrosis and cirrhosis

PRP (platelet-rich plasma) as an innovative aid for liver regeneration in chronic liver damage

The liver is considered a miracle organ of regeneration - even after major tissue damage, it can renew itself to an astonishing degree. But what happens when chronic damage such as fatty liver, fibrosis or cirrhosis overtax the liver's ability to heal itself?

This is where an innovative approach from regenerative medicine comes in: Platelet-rich plasma (PRP) - a concentrate full of growth factors and cytokines obtained from the patient's own blood. Imagine the body's own blood platelets (thrombocytes) becoming "mini-pharmacists" that release healing impulses at the site of liver damage.

It is precisely this vision - the support of liver regeneration through PRP - that we want to shed light on in this article.

It is important to be realistic:
PRP in liver therapy is still at the experimental stage and is not an established standard treatment - any use must be carried out with appropriate caution and legal certainty.

Liver regeneration and PRP in a clinical context

The liver has an almost mythical regenerative capacity - think of the Greek legend of Prometheus, whose liver, eaten daily by an eagle, grew back overnight. In fact, a human liver can grow back considerably after partial removal. Nevertheless, modern doctors are reaching their limits when it comes to chronic liver diseases: Persistent damage caused by fat deposits, inflammation or toxins leads to scarring (fibrosis) and even cirrhosis, a final stage with nodular remodeling in which the regenerative capacity is exhausted. Diseases such as non-alcoholic fatty liver disease (NAFLD) and its inflammatory increase NASH (non-alcoholic steatohepatitis) are now on the rise worldwide due to overeating and diabetes. Effective drug therapies are largely lacking, apart from lifestyle changes - in the late stages, liver transplantation is often the only option.

Against this background, clinical researchers are looking for new regenerative therapy approaches. One promising candidate is platelet-rich plasma (PRP), a concentrate of thrombocytes (blood platelets) obtained from the patient's blood. PRP is already used in other medical fields, such as wound healing, orthopaedics and aesthetic medicine, to stimulate healing processes. Could the growth factors in platelets also help the damaged liver? In this specialist article, we examine the current state of knowledge on liver regeneration with PRP - from biological mechanisms of action and potential areas of application (NAFLD, NASH, fibrosis, cirrhosis) to practical implementation and the legal framework in Germany. It is important to note that PRP is not a miracle cure and no promises of a cure are made - the following presentation is intended to provide realistic, scientifically sound insights for healthcare professionals.

Biological mechanisms of action of PRP in liver regeneration

PRP (platelet-rich plasma) exerts its effect in the liver via several coordinated biological signaling pathways, which have a targeted effect on central pathological processes such as cell loss, fibrosis, chronic inflammation and microcirculatory disorders. The thrombocytes contained in PRP are far more than mere blood clotting cells - they function as highly active cell components that specifically release regeneration-promoting messenger substances in the event of tissue damage.

1. Promotion of hepatocyte proliferation

Platelets contain growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), IGF-1 and PDGF. These messenger substances stimulate dormant liver cells to proliferate, stimulate the division of liver stem cells and support the restoration of damaged tissue structures. Studies show that PRP increases DNA synthesis in hepatocytes and reactivates the cell cycle in vitro and in animal models.

2. Modulation of the immune response

A remarkable effect of PRP is its ability to influence the balance of the immune response. While acute liver injury is usually accompanied by massive activation of pro-inflammatory macrophages (M1), PRP promotes conversion to the M2 phenotype - a cell form that secretes anti-inflammatory cytokines such as IL-10 and supports repair processes. This polarization helps to limit chronic inflammation while promoting regeneration.

3. Inhibition of fibrotic signaling pathways

PRP contains molecules that can specifically inhibit the activation of hepatic stellate cells - the main cause of liver fibrosis. Particularly relevant is the proven inhibition of transforming growth factor beta 1 (TGF-β1), a key cytokine in collagen synthesis. By reducing TGF-β1 expression and simultaneously promoting anti-fibrotic enzymes such as matrix metalloproteinases, PRP can not only prevent the formation of new scars, but also contribute to the restructuring of existing scar tissue.

4. Promotion of microcirculation

The regenerating liver is dependent on good blood circulation. In addition to VEGF, PRP also contains sphingosine-1-phosphate (S1P), a lipid mediator that stimulates the formation and opening of the finest blood vessels in the liver. By improving microcirculation, the affected tissue is better supplied with oxygen and nutrients - a decisive factor for cell survival and healing.


To summarize:
PRP does not act one-dimensionally in the liver, but orchestrates a complex network of regenerative, inflammation-modulating and anti-fibrotic signals. This combination makes PRP a promising tool in translational hepatology - even if it is currently still an experimental therapeutic procedure.

Why should a blood concentrate of all things help the liver to heal?
The answer lies in the special ingredients of PRP. Platelets contain numerous growth factors and cytokines in their granules, which are released when tissue is damaged.

In PRP, these natural healing factors are made directly available in high concentrations. In the following, we look at four central mechanisms of action through which PRP could support the damaged liver:

  1. Promotion of cell regeneration

  2. Inhibition of fibrosis

  3. Inflammation modulation

  4. Improvement of microcirculation

Biological mechanisms of action of PRP in liver regeneration

1: Schematic representation of the main biological effects of PRP in liver regeneration.
(A) Growth factors such as HGF, IGF-1 and VEGF promote hepatocyte proliferation and albumin synthesis.
(B) PRP polarizes macrophages towards the anti-inflammatory M2 phenotype and supports tissue repair.
(C) PRP and its extracellular vesicles inhibit the expression of TGF-β1 and thereby reduce fibrosis signaling pathways.

(D) Angiogenic mediators such as VEGF and S1P improve microcirculation and oxygenation in liver tissue.

Source: https://www.wjgnet.com/2219-2832/

Liver regeneration with PRP

Promotion of cell regeneration

Chronic liver damage is associated with the loss of functional liver cells. One of the main aims of therapy is therefore to stimulate the formation of new hepatocytes (liver cells). PRP can start here by releasing an abundance of regeneration-promoting factors.

Platelets contain, among other things:

  • Hepatocyte growth factor (HGF)

  • Insulin-like growth factor 1 (IGF-1)

  • Vascular endothelial growth factor (VEGF)

These factors have been shown in studies to induce dormant liver cells to divide and trigger liver cell proliferation.

In vitro experiments support this: When PRP is added to liver cells, there is a strong mitotic activation - the cells enter the cell cycle from a quiescent state, driven by the signals released by the platelets).

Other growth factors in PRP also play a role:
PRP contains, among other things, PDGF (platelet-derived growth factor) and EGF (epidermal growth factor), which support tissue repair and the formation of new blood vessels.

Taken together, these messenger substances act like a "regeneration cocktail": they promote the division of hepatocytes, stimulate liver stem cells and promote the repair of damaged tissue.

Data from animal experiments show that the liver exhibits increased regenerative cell growth after PRP administration.

In a mouse model, for example, high platelet counts led to early activation of the PI3K/Akt and IL-6/STAT3 signaling pathways, which are essential for liver regeneration.

In short:
PRP provides the exhausted liver with new "building materials" and starting signals to replace lost cells.

PRP regenerative mechanisms

Inhibition of liver fibrosis

One of the most dangerous consequences of chronic liver damage is fibrosis - scarring of the liver tissue due to excessive collagen deposition.

PRP could counteract this by

  1. influencing the hepatic stellate cells (the main cause of fibrosis),

  2. inhibitingfibrosis-promoting signaling pathways,

  3. supportingdegradative processes in the connective tissue.

Inhibition of stellate cell activation

Experimental findings indicate that platelets can inhibit the activation of stellate cells - among other things through the release of adenosine and other mediators.

In animal models, PRP was shown to significantly reduce the expression of fibrosis-associated genes, which was associated with less scarring.

TGF-β1 - the key to inhibiting fibrosis

A key player in fibrosis is transforming growth factor beta 1 (TGF-β1) - it activates stellate cells and stimulates collagen production.

PRP or its extracellular vesicles have been shown to reduce the expression of TGF-β1 in damaged liver tissue.

If TGF-β1 is slowed down, the excessive formation of connective tissue decreases - the liver regains space for regeneration.

Remodeling of scar tissue

PRP not only promotes the inhibition of fibrosis, but also the breakdown of existing scar structures.
For example, HGF (hepatocyte growth factor) activates so-called matrix metalloproteinases (MMPs), which can dissolve collagen fibers.

All in all, this results in an anti-fibrotic effect:

  • Less formation of new scars

  • Possible remodeling of existing scarring

  • Improved histology in animal studies

In preclinical studies, PRP administration led to less connective tissue septa formation and significantly reduced fibrotic gene expression.

Scientists are increasingly reporting "anti-fibrotic properties" of platelet therapy - a promising approach in the treatment of chronic liver damage.

Anti-inflammatory effects

Chronic liver diseases such as NASH or hepatitis B/C are associated with permanent inflammation that continuously damages the liver tissue. PRP can help to modulate these harmful processes, not just block them.

Dual role of platelets

PRP not only promotes the inhibition of fibrosis, but also the breakdown of existing scar structures.
For example, HGF (hepatocyte growth factor) activates so-called matrix metalloproteinases (MMPs), which can dissolve collagen fibers.

All in all, this results in an anti-fibrotic effect:

  • Less formation of new scars

  • Possible remodeling of existing scarring

  • Improved histology in animal studies

In preclinical studies, PRP administration led to less connective tissue septa formation and significantly reduced fibrotic gene expression.

Scientists are increasingly reporting "anti-fibrotic properties" of platelet therapy - a promising approach in the treatment of chronic liver damage.

Thrombocytes

M2 polarization: From attacker to healer

Several studies show that PRP induces a polarization of macrophages towards the M2 phenotype - these are the "healers" among the immune cells.
They release IL-10, an anti-inflammatory cytokine, and promote tissue repair.

In a mouse model of liver cirrhosis, the administration of PRP vesicles led to an increase in these healing-promoting macrophages in the liver.

At the same time, liver values such as ALT decreased significantly - an indication of reduced inflammation and cell damage.

Inflammation regulation through PRP cytokines

Platelets themselves contain a large number of cytokines - including

  • TNF-α

  • IL-6

  • IL-1β

These do not have a toxic effect at low doses, but start the regeneration phase by bringing hepatocytes out of "sleep mode" - a process known as "priming"(source: WJGNet).

Reduce oxidative stress

In a Study the concentration of glutathione (a powerful antioxidant) in the liver increased significantly after PRP administration, while malondialdehyde (MDA) - a marker for lipid peroxidation - decreased.

Less oxidative stress = less inflammatory stimulus = more chance of regeneration

To summarize:
PRP has an inflammation-modulating effect, not an immunosuppressive one:
It reduces harmful inflammation, but at the same time promotes reparative immune responses - a decisive advantage over classic anti-inflammatory drugs.

Improvement of the microcirculation

An often overlooked aspect of chronic liver disease is impaired microcirculation:

Inflammation and fibrosis constrict or block the fine liver sinusoids (capillaries), which severely impairs the supply of oxygen and nutrients to the hepatocytes.

PRP promotes angiogenesis

Platelet-rich plasma (PRP) contains high concentrations of:

  • VEGF (vascular endothelial growth factor)

  • Angiopoietins

  • S1P (sphingosine-1-phosphate)

These substances promote the sprouting of new capillaries - especially in damaged tissue.

New microvessels not only improve blood circulation - they also create a regeneration-friendly environment.

S1P: The underestimated regulator

S1P, which is released when platelets come into contact with the endothelium, acts directly on endothelial cells and promotes:

  • Vasodilatation

  • Permeability of the sinusoids

  • IL-6 production in sinusoidal cells, which in turn triggers liver regeneration

PRP therefore not only improves the "what" (nutrient supply), but also the "how" (vessel width, endothelial function).

Tissue flow and oxygen supply

Improved microcirculation means:

  • More oxygen for hepatocytes

  • Less hypoxic damage

  • Better uptake of regenerative signals

Well perfused tissue is less prone to fibrosis than tissue that is chronically undersupplied.

Indirect references from other departments

It is known from wound healing that PRP injections can visibly improve local blood flow.
Even if this effect has not yet been clinically quantified in the liver, animal studies suggest a plausible benefit.

To summarize:
PRP acts like a "horticulturist" in the microcirculation of the liver - it plants new vessels, improves the flow conditions and supplies the cells with what they need to survive and regenerate.

Chronic liver diseases as potential areas of application

Now that we have shed light on the biological principles of action, the question arises:
For which specific liver diseases could PRP be useful?

Chronic liver damage has many faces. The focus is particularly on

  1. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

  2. Liver fibrosis due to toxic, infectious or metabolic causes

  3. Liver cirrhosis - the final stage of chronic liver damage

Non-alcoholic fatty liver disease (NAFLD) and NASH

NAFLD is one of the most common chronic liver diseases worldwide - sometimes silent, sometimes with dangerous progression to inflammatory NASH and ultimately fibrosis.

PRP could have an effect here in several areas:

  • Inhibition of inflammatory immune cells

  • Promotion of M2 macrophages (healing-promoting)

  • Reduction of oxidative stress

  • Stimulation of regenerative signaling pathways

In an animal model of fatty liver hepatitis, PRP was able to reduce the extent of liver damage, improve liver enzymes and limit oxidative damage(source: ASMJ).

Although PRP is not established in guideline treatment, the mechanisms fit exactly with the pathophysiology of NASH: inflammation, fibrosis, cell stress and regenerative needs.

Study: https://www.imrpress.com/journal/FBL/30/3/10.31083/FBL26748

PRP and NAFLD NASH Liver

Liver fibrosis of various causes

Whether due to:

  • chronic viral hepatitis (HBV/HCV)

  • Toxins such as alcohol or medication

  • or metabolic causes

- Fibrosis always means that functional liver tissue is replaced by connective tissue.

PRP could help to slow down or reverse this process.

In animal models with thioacetamide- or CCl₄-induced fibrosis, PRP showed

  • Less collagen deposition

  • Reduction of fibrotic markers

  • Better histology and cell architecture

Some findings suggest that PRP could also loosen existing scar structures, e.g. by stimulating matrix metalloproteinases (MMPs).

Particularly exciting: In a mouse model, more anti-apoptotic markers were found in hepatocytes after PRP administration - signs that cells in the fibrosis zone were able to survive and expand.

Liver cirrhosis in an advanced stage

Cirrhosis is the final stage - non-functional regenerative nodules, scars, portal hypertension.
The liver is structurally severely damaged. Can PRP still help here?

A pilot study from Japan showed that platelet transfusions in cirrhosis patients

  • increased serum albumin

  • Improvedcholinesterase levels

  • Reduced fibrosis markers

These results can be interpreted as evidence for the effect of platelet-mediated signaling.

However, in advanced cirrhosis (Child C) there are often too few functional platelets available to produce autologous PRP.

PRP could be considered here more as a bridge therapy in moderate stages - for stabilization before a liver transplant.

PRP treatment of liver cirrhosis

Obtaining and using PRP in practice

How would PRP be used for liver regeneration in practice? Let's take a look at how PRP is produced and how it finds its way into the liver, as well as what materials are required. Again, it is important to emphasize: Such applications belong exclusively in the hands of medical professionals and ideally in study protocols, as it is an experimental procedure.

PRP preparation: from blood to healing concentrate

The preparation takes place in several steps and requires sterile conditions and suitable equipment:

  1. Blood collection:
    15-60 ml of venous blood is filled into special PRP tubes from PRPMED, which already contain an anticoagulant.

  2. Centrifugation:
    The blood is centrifuged in a PRP centrifuge for medical applications

PRP production

Materials at a glance

Complete sets with tubes, syringes and centrifuge are available in the PRPmed online shop suitable for medical practices, clinics and study centers.

PRP and the liver: how the body's own pharmacy could boost regeneration

The idea that the growth factors contained in PRP could positively influence liver regeneration is based on sound biological considerations. The liver is a highly vascularized organ and an adequate blood supply is essential for its regeneration.

Growth factors such as VEGF could promote the formation of new blood vessels in the damaged liver and thus improve the supply of oxygen and nutrients. Other factors, such as HGF (hepatocyte growth factor), which is also found in platelets, are known stimulators of hepatocyte proliferation. A targeted release of these factors by PRP could therefore directly stimulate the division and growth of liver cells.

Furthermore, inflammatory processes play an ambivalent role in liver diseases. While acute inflammation can be part of the healing process, chronic inflammation fuels the development of fibrosis. PRP also contains inflammation-modulating factors that could help to dampen an excessive or chronic inflammatory response in the liver and thus improve the regenerative milieu.

Some Studies suggest that PRP may also have anti-fibrotic properties by influencing the activity of cells responsible for scar formation (hepatic stellate cells). The combined effect - stimulating cell proliferation, promoting angiogenesis, modulating inflammation and potentially reducing fibrosis - makes PRP an intriguing candidate for supporting liver regeneration, especially when it comes to PRP treatment of the liver.

Application routes: How does PRP reach the liver?

  • Intravenous infusion

    • Simple and low-risk

    • PRP is distributed systemically, but accumulates preferentially in damaged tissue

    • Functionally effective in animal models

  • Intrahepatic injection (under ultrasound)

    • Targeted depot injection into the parenchyma

    • Highest local drug concentration

    • Invasive, with risk of bleeding - only for experienced centers

  • Portal venous or arterial application (experimental)

    • Catheter-based via hepatic artery or portal vein

    • Precise control, e.g. for interventional procedures

  • Intraoperatively during liver resection

    • PRP as a regeneration booster for partial liver removal

    • Positive effects proven in animal models

To summarize:
PRP application in the liver is technically feasible - but requires medical expertise, suitable devices and a clear indication.
In the next part, we look at the study situation and clinical evidence.

A look into the research crucible: What do studies say about PRP application for liver diseases?

Research into the use of PRP for liver diseases is still at an early stage compared to other medical fields such as orthopaedics or dermatology, but is already showing promising approaches. Most of the findings to date have come from preclinical studies on animal models of liver damage.

Various studies have shown that the administration of PRP in animal models with acute or chronic liver damage can lead to an improvement in liver function, a reduction in inflammatory markers and reduced fibrosis development. For example, PRP has been observed to accelerate the regeneration of hepatocytes and reduce apoptosis (programmed cell death) of liver cells. Some studies also suggest that PRP can upregulate the expression of genes involved in liver regeneration.

A comprehensive review by Zhang et al. (2025) on the role of platelet-rich plasma in biomedicine emphasizes the broad potential of PRP to promote tissue repair and regeneration through its anti-inflammatory and growth-promoting factors, even if the focus is not specifically on the liver. The mechanisms described there, such as the release of growth factors (PDGF, TGF-β, VEGF, IGF-1), which stimulate cell proliferation, angiogenesis and the modulation of immune cells, are also highly relevant for liver regeneration.

Clinical studies in humans on direct PRP treatment of the liver are still rare, but the growing understanding of the mechanisms of action and the positive results from preclinical models and other regenerative fields are raising hopes. Further well-designed clinical trials are needed to evaluate the efficacy, safety and optimal mode of application of PRP in various liver diseases in humans. The challenge also lies in the standardization of PRP production and application protocols in order to achieve comparable and reproducible results.

In summary:
PRP application in the liver is technically feasible - but requires medical expertise, suitable devices and a clear indication.

Current study situation and clinical evidence

Although PRP is already being used and studied in many medical fields (orthopaedics, dermatology, sports medicine), the evidence for PRP in liver diseases is still in its infancy. However, there are a growing number of preclinical studies and initial clinical experience reports that paint a cautious picture.

  • Animal studies:

Several papers in rats and mice provide proof-of-concept data. For example, an Iranian research group studied PRP in rats with CCl_4-induced liver injury (a common fibrosis model). They found that PRP was not toxic to the liver and mitigated the damage caused by CCl_4 pmc.ncbi.nlm.nih.gov. Specifically, liver enzymes were lower in the PRP group, tissue showed less necrosis and fatty changes, and oxidative stress markers were reduced pmc.ncbi.nlm.nih.gov | pmc.ncbi.nlm.nih.gov.

Another study (Shoieb et al. 2018) using a thioacetamide fibrosis model reported that PRP improved liver histology and suppressed the fibrotic and inflammatory response asmj.journals.ekb.eg.

PRP-treated animals had higher antioxidant capacities and less inflammatory cytokines in the tissue. Another interesting finding was that PRP reduced the expression of pro-apoptotic genes, meaning that fewer liver cells died asmj.journals.ekb.eg. This is important because every cell death avoided is a gain for regeneration. Overall, these animal data suggest that PRP has a multi-factorial positive effect on the damaged liver: less inflammation, less fibrosis, less cell death and a tendency towards more regeneration.

A highly topical approach is the use of PRP-derived extracellular vesicles (PRP-EVs), i.e. the exosomes/microvesicles obtained from PRP that transport the decisive factors. in 2024, a Japanese working group led by Maeda et al. published a study in which mice with cirrhosis were injected with these PRP-EVs. The results were remarkable: cirrhosis improved in the animal model, as measured by a lower degree of fibrosis and improved liver values pmc.ncbi.nlm.nih.gov. Mechanistically, they showed that the PRP vesicles upregulated regenerative genes (e.g. albumin, VEGF) and downregulated TGF-β1, and also polarized macrophages towards M2 pmc.ncbi.nlm.nih.gov | pmc.ncbi.nlm.nih.gov. The authors conclude that PRP-EVs contribute to hepatocyte proliferation, anti-inflammation and anti-fibrosis and thus represent a novel therapeutic pathway for cirrhosis pmc.ncbi.nlm.nih.gov. This study emphasizes the previously explained mechanisms using state-of-the-art molecular methods.

  • Clinical evidence:

There is very little data on human patients to date. Worth mentioning is the aforementioned pilot study from Japan (Maruyama et al.), in which 10 patients with chronic liver disease and cirrhosis received weekly platelet transfusions. After 12 weeks, there was a significant improvement in serum albumin and cholinesterase (an enzyme produced by the liver) jstage.jst.go.jp | jstage.jst.go.jpwhich indicates better liver function. Fibrosis markers such as hyaluronic acid tended to decrease jstage.jst.go.jp. However, mild side effects also occurred (itching, urticaria in some patients due to the foreign transfusion) jstage.jst.go.jp | jstage.jst.go.jp. Since PRP is autologous, such immunological side effects would not be expected. The authors were positive about the results, but emphasized that this was a small, uncontrolled study.

Another clinical publication (Polukarova et al. 2019) looked at the feasibility of PRP in cirrhosis patients. They prepared PRP from the blood of 12 cirrhosis patients and analyzed the platelet counts. As mentioned, the yield was limited - on average, the platelet concentration could only be increased 2.4-fold (compared to ~3.3-fold in healthy individuals) apcz.umk.pl.

They came to the conclusion that autologous PRP cannot achieve the necessary "dose" to be effective in cases of pronounced thrombocytopenia in cirrhosis apcz.umk.pl, and called for improvements in PRP collection (possibly larger blood volumes, other preparation methods). This finding calls for caution: the patients to be treated often have precisely the parameters that make PRP difficult (few and weak platelets).

As far as can be seen, there are currently no major clinical studies on PRP injections for chronic liver fibrosis/cirrhosis. However, there are case reports in congress abstracts where, for example, PRP has been used in individual patients with fatty liver, but without publication of detailed results. The overlap with other regenerative therapies (such as stem cell therapy) is also being investigated; one paper showed, for example, that the combination of mesenchymal stem cells with PRP could have a synergistic effect in an animal model, while PRP alone had no statistically significant effect pubmed.ncbi.nlm.nih.gov | mdpi.com - This makes it clear that the effect strength of PRP alone may be moderate and that there is more potential in combinations.

Overall, the status can be summarized as follows: Preclinical evidence supports the use of PRP for liver injury, with consistent evidence of protective, antifibrotic and regenerative effects in animal models pmc.ncbi.nlm.nih.gov | asmj.journals.ekb.eg.

Clinical data on humans is still very limited and in some cases contradictory, meaning that no reliable statements can be made regarding efficacy. However, there is cautious curiosity among experts. In view of the great need for new therapies (e.g. against NASH or to prevent transplants), there is great interest in further researching PRP in studies. The first steps could be controlled studies in patients with moderate fibrosis to test safety, feasibility and preliminary efficacy.

Conclusion and outlook: A glimmer of hope on the horizon of liver therapy?

The idea of awakening the dormant regenerative power of the liver with the help of its own platelet-rich plasma is fascinating and opens up new horizons in the treatment of chronic liver diseases. PRP brings with it a bundle of growth factors, cytokines and enzymes that target the central problems of a diseased liver: Cell loss, inflammation, fibrosis and circulatory dysfunction. Preclinical research suggests that PRP may actually act as a multitool - promoting liver cell regeneration, curbing scarring, calming overactive immune responses and improving the microvascular milieu pmc.ncbi.nlm.nih.gov | pmc.ncbi.nlm.nih.gov. For many patients with diseases such as NASH or incipient cirrhosis, this raises hope for a gentle, personalized therapy derived from their own blood.

However, we are still at the beginning. Before PRP finds its way from the laboratory to the clinic, careful studies are needed to clarify questions: Which patients will benefit the most? At what stage of the disease is PRP useful? How often and in what dose should it be administered? And of course: Do the benefits really outweigh the risks and placebo effects? Only when clear results are available can broader use be considered. Until then, PRP for liver regeneration remains an exciting field of translational research that we should continue to pursue with scientific curiosity, but also with clinical responsibility.

For healthcare professionals, this means staying informed, critically examining initial study results and providing realistic information to interested patients. It is possible that pilot centers offering PRP therapies as part of studies will emerge in the coming years. If the initial optimism is confirmed, PRP could one day find its way into multimodal therapy for chronic liver diseases - whether to slow down fibrosis, bridge the waiting time for a transplant or promote recovery after severe liver damage. Until then, however, PRP is still an experimental hope and not a miracle cure. The liver is a patient fighter - with a little support from modern therapies such as PRP, we may be able to give it a decisive helping hand in the future to overcome even the most severe damage. The coming years of research will show whether this hope will become a tangible medical reality.

Liver regeneration using PRP is an exciting and developing field of research that has the potential to revolutionize the treatment of liver disease in the future.

The ability of PRP to deliver a concentrate of endogenous growth factors and healing substances directly to the site of damage offers a logical and biologically sound approach to supporting the liver's natural self-healing powers.

Preclinical data to date is encouraging and indicates positive effects on cell proliferation, inflammation modulation and fibrosis reduction.

The use of high-quality materials, such as specific PRP tubes and precise PRP centrifuges, is a basic prerequisite for the production of an effective therapeutic agent.

Even if the path to the widespread clinical application of PRP in liver diseases will still be characterized by further intensive research and clinical studies, a promising horizon is already emerging. The optimization of PRP production protocols, the identification of ideal patient groups and the combination with other therapeutic approaches could further increase its effectiveness.

PRP treatment of the liver could thus become an important building block in regenerative medicine and give new hope to patients with impaired liver function. It remains an exciting journey that science and medicine are embarking on together to unlock the full potential of this endogenous healing power.

Disclaimer

This blog post is intended solely as professional information for healthcare professionals and does not constitute medical advice. The information presented here is in no way a substitute for individual advice, diagnosis or treatment by a qualified doctor or other healthcare professional. Patients should always make any medical decisions or changes to their treatment in consultation with their treating physician. The authors and publishers assume no liability for possible disadvantages or damages that could result from the use of the information presented here.

References

  • Platelet therapy: A novel strategy for liver regeneration, anti-fibrosis, and anti-apoptosis

https://www.wjgnet.com/2219-2832/full/v3/i3/29.htm

  • Effect of Platelet-Rich Plasma on CCl4-Induced Chronic Liver Injury in Male Rats - PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC3953414/

  • Platelet therapy: A novel strategy for liver regeneration, anti-fibrosis, and anti-apoptosis

https://www.wjgnet.com/2219-2832/full/v3/i3/29.htm

    • Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease

    https://www.imrpress.com/journal/FBL/30/3/10.31083/FBL26748/htm

    • Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice - PubMed

    https://pubmed.ncbi.nlm.nih.gov/39569343/

    • Effect of Platelet-Rich Plasma on CCl4-Induced Chronic Liver Injury in Male Rats - PMC

    https://pmc.ncbi.nlm.nih.gov/articles/PMC3953414/

    • Synergistic Hepatoprotective Effects of Mesenchymal Stem Cells and Platelet-Rich Plasma in a Rat Model of Bile Duct Ligation-Induced Liver Cirrhosis - PubMed

    https://pubmed.ncbi.nlm.nih.gov/38474368/

    • Effect of Platelet-Rich Plasma on CCl4-Induced Chronic Liver Injury in Male Rats - PMC

    https://pmc.ncbi.nlm.nih.gov/articles/PMC3953414/

    • Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice - PubMed

    https://pubmed.ncbi.nlm.nih.gov/39569343/

    • Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice - PubMed

    https://pubmed.ncbi.nlm.nih.gov/39569343/

    • Technology Intended to Improve Patient Care - Cytori Therapeutics

    https://www.cytori.com/our-technology/

    • Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy - PubMed

    https://pubmed.ncbi.nlm.nih.gov/34095367/

    Related products

    DUO PRF/PRP centrifuge DUO PRF/PRP centrifuge 2
    immediately available
    Certified Class IIa medical device – specifically designed for PRF and PRP therapies. Maximum speed of 4500 RPM and RCF up to 2490 x g for precise and safe blood preparation. Quiet operation at only 56 dB – ideal for use in quiet clinic or practice environments. User-friendly controls with pre-set programs and easy parameter adjustments. Highest...
    PRP tubes | PRP-Pro | PU 10 pcs. PRP tubes | PRP-Pro | PU 10 pcs. 2
    immediately available
    PRP

    PRP tubes | Vi PRP-PRO | with Anticoagulant PU 10 pieces

    PRPMED Professional Cosmetic Treatments
    100101
    €110.08
    VI PRP-PRO | PRP Tubes – The Revolution in Plasma Treatment The VI PRP-PRO glass tube offers a modern solution for producing platelet-rich plasma (PRP) and ensures additional stability and reliability in treatments with a wall thickness of 2.4 mm. Developed with innovative technology and EC-certified (0425-MED-004180-00), it guarantees the highest level...
    PRP/CGF Tubes | without anticoagulants | PU 10 pcs.
    immediately available
    Density Platelet Gel PRP/CGF tubes provide a simple and efficient method for obtaining and preparing platelet-rich plasma (PRP) from patients' blood. Caution. These tubes do not contain separating gel and are without anticoagulants.   

    Comments (0)

    No comments at this moment
    Product added to wishlist
    Product added to compare.
    group_work Cookie consent